content/01.introduction.md:4:NSCLC
content/01.introduction.md:6:Indeedm
content/01.introduction.md:6:supressive
content/01.introduction.md:8:adenocarcinomas
content/01.introduction.md:8:alveoli
content/01.introduction.md:8:BRAF
content/01.introduction.md:8:EGFR
content/01.introduction.md:8:genomic
content/01.introduction.md:8:histological
content/01.introduction.md:8:histological
content/01.introduction.md:8:KRAS
content/01.introduction.md:8:MAPK
content/01.introduction.md:8:NSCLC
content/01.introduction.md:8:NSCLC
content/01.introduction.md:8:SCLC
content/01.introduction.md:8:subtype
content/01.introduction.md:10:metastaized
content/01.introduction.md:12:ALK
content/01.introduction.md:12:autophagy
content/01.introduction.md:12:BRAF
content/01.introduction.md:12:Carboplatin
content/01.introduction.md:12:chemotherapeutics
content/01.introduction.md:12:Cisplatin
content/01.introduction.md:12:EGFR
content/01.introduction.md:12:immunotherapy
content/01.introduction.md:12:immunotherapy
content/01.introduction.md:12:inhibtion
content/01.introduction.md:12:MEK
content/01.introduction.md:12:Paclitaxel
content/01.introduction.md:12:Pemetrexed
content/01.introduction.md:12:ROS
content/01.introduction.md:12:TRK
content/01.introduction.md:14:MAPK
content/01.introduction.md:16:ARAF
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:BRAF
content/01.introduction.md:16:constitutively
content/01.introduction.md:16:CRAF
content/01.introduction.md:16:effciency
content/01.introduction.md:16:EGF
content/01.introduction.md:16:EGF
content/01.introduction.md:16:glutamic
content/01.introduction.md:16:GTP
content/01.introduction.md:16:GTP
content/01.introduction.md:16:GTP
content/01.introduction.md:16:GTP
content/01.introduction.md:16:independet
content/01.introduction.md:16:kinases
content/01.introduction.md:16:kinases
content/01.introduction.md:16:kinases
content/01.introduction.md:16:Kinases
content/01.introduction.md:16:ligand
content/01.introduction.md:16:ligand
content/01.introduction.md:16:ligands
content/01.introduction.md:16:MAPK
content/01.introduction.md:16:MAPK
content/01.introduction.md:16:mitogens
content/01.introduction.md:16:NGF
content/01.introduction.md:16:oncogenic
content/01.introduction.md:16:oncogenic
content/01.introduction.md:16:phosphorylates
content/01.introduction.md:16:phosphorylates
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RAS
content/01.introduction.md:16:RTKs
content/01.introduction.md:16:RTKs
content/01.introduction.md:16:transcriptional
content/01.introduction.md:16:Tyrosine
content/01.introduction.md:16:valine
content/01.introduction.md:18:autophagy
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:BRAF
content/01.introduction.md:18:Dabrafenib
content/01.introduction.md:18:kinases
content/01.introduction.md:18:MAPK
content/01.introduction.md:18:MEK
content/01.introduction.md:18:MEK
content/01.introduction.md:18:pre
content/01.introduction.md:18:Trametinib
content/01.introduction.md:22:BRAF
content/01.introduction.md:22:LUAD
content/01.introduction.md:24:adenocarcinomas
content/01.introduction.md:24:adenomas
content/01.introduction.md:24:BRAF
content/01.introduction.md:24:BRAF
content/01.introduction.md:24:BRAF
content/01.introduction.md:24:BRAF
content/01.introduction.md:24:EGFR
content/01.introduction.md:24:GEMMs
content/01.introduction.md:24:Hanahan
content/01.introduction.md:24:KRAS
content/01.introduction.md:24:MAPK
content/01.introduction.md:24:oncogenic
content/01.introduction.md:24:pneumocytes
content/01.introduction.md:24:Surfactant
content/01.introduction.md:24:WNT
content/01.introduction.md:26:proto
content/01.introduction.md:29:GEMMs
content/01.introduction.md:31:DMBA
content/01.introduction.md:31:FVB
content/01.introduction.md:31:GEMMs
content/01.introduction.md:31:lethality
content/01.introduction.md:31:lethality
content/01.introduction.md:33:Cre
content/01.introduction.md:33:Cre
content/01.introduction.md:33:inducible
content/01.introduction.md:33:KRAS
content/01.introduction.md:33:LoxP
content/01.introduction.md:33:LoxP
content/01.introduction.md:33:LoxP
content/01.introduction.md:33:polyadenylation
content/01.introduction.md:33:recombinase
content/01.introduction.md:35:BRAF
content/01.introduction.md:35:preclinical
content/01.introduction.md:35:transcriptional
content/01.introduction.md:37:BRAF
content/01.introduction.md:37:BRAF
content/01.introduction.md:37:BRAF
content/01.introduction.md:37:BRAF
content/01.introduction.md:37:CAAX
content/01.introduction.md:37:cDNA
content/01.introduction.md:37:Cre
content/01.introduction.md:37:Cre
content/01.introduction.md:37:fluorophore
content/01.introduction.md:37:LoxP
content/01.introduction.md:37:LoxP
content/01.introduction.md:37:onco
content/01.introduction.md:37:oncoprotein
content/01.introduction.md:37:TdTomato
content/01.introduction.md:39:egfr
content/01.introduction.md:39:erk
content/01.introduction.md:39:mek
content/01.introduction.md:39:ras
content/01.introduction.md:41:luad
content/01.introduction.md:41:tumorigenesis
content/01.introduction.md:43:BRAF
content/01.introduction.md:43:gemms
content/01.introduction.md:47:wnt
content/01.introduction.md:52:WNT
content/01.introduction.md:54:decameric
content/01.introduction.md:54:oligomerization
content/01.introduction.md:54:tetramerization
content/01.introduction.md:54:transactivation
content/01.introduction.md:54:transactivation
content/01.introduction.md:54:transcriptional
content/01.introduction.md:54:transcriptional
content/01.introduction.md:54:transcriptional
content/01.introduction.md:56:Fraumeni
content/01.introduction.md:56:leukemias
content/01.introduction.md:60:phenotypes
content/01.introduction.md:60:stressor
content/01.introduction.md:62:cDNA
content/01.introduction.md:62:ectopic
content/01.introduction.md:62:misclassification
content/01.introduction.md:62:RAS
content/01.introduction.md:64:hemizygosity
content/01.introduction.md:64:hotspot
content/01.introduction.md:64:hotspots
content/01.introduction.md:64:tetramer
content/01.introduction.md:64:transcriptional
content/01.introduction.md:66:chemoresistance
content/01.introduction.md:66:Fraumeni
content/01.introduction.md:66:Fraumeni
content/01.introduction.md:66:GOF
content/01.introduction.md:66:GOF
content/01.introduction.md:66:LOF
content/01.introduction.md:66:LOF
content/01.introduction.md:66:missense
content/01.introduction.md:66:missense
content/01.introduction.md:66:tumorigenic
content/01.introduction.md:68:Catenin
content/01.introduction.md:68:CREB
content/01.introduction.md:68:GOF
content/01.introduction.md:68:KRAS
content/02.tubaseq.md:7:bona
content/02.tubaseq.md:7:fide
content/02.tubaseq.md:7:GEMMs
content/02.tubaseq.md:7:GEMMs
content/02.tubaseq.md:7:scalable
content/02.tubaseq.md:7:suboptimal
content/02.tubaseq.md:9:barcoded
content/02.tubaseq.md:9:BRAF
content/02.tubaseq.md:9:Cre
content/02.tubaseq.md:9:Cre
content/02.tubaseq.md:9:endoing
content/02.tubaseq.md:9:lentiviral
content/02.tubaseq.md:9:mor
content/02.tubaseq.md:9:rcode
content/02.tubaseq.md:9:recombinase
content/02.tubaseq.md:9:uencing
content/02.tubaseq.md:9:Winslow
content/02.tubaseq.md:11:barcode
content/02.tubaseq.md:11:barcode
content/02.tubaseq.md:11:barcoded
content/02.tubaseq.md:11:Cre
content/02.tubaseq.md:11:genotype
content/02.tubaseq.md:11:genotypes
content/02.tubaseq.md:11:Lenti
content/02.tubaseq.md:11:sgID
content/02.tubaseq.md:11:sgID
content/02.tubaseq.md:11:sgRNA
content/02.tubaseq.md:11:sgRNA
content/02.tubaseq.md:11:Winslow
content/02.tubaseq.md:15:BRAF
content/02.tubaseq.md:17:adenomas
content/02.tubaseq.md:17:adenomas
content/02.tubaseq.md:17:adenomas
content/02.tubaseq.md:17:adenomas
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:BRAF
content/02.tubaseq.md:17:doublings
content/02.tubaseq.md:17:doublings
content/02.tubaseq.md:17:histological
content/02.tubaseq.md:17:Oncogenic
content/02.tubaseq.md:17:stromal
content/02.tubaseq.md:17:tumorigenesis
content/02.tubaseq.md:17:WNT
content/02.tubaseq.md:19:barcode
content/02.tubaseq.md:19:barcoded
content/02.tubaseq.md:19:barcoded
content/02.tubaseq.md:19:barcoded
content/02.tubaseq.md:19:BRAF
content/02.tubaseq.md:19:BRAF
content/02.tubaseq.md:19:Cre
content/02.tubaseq.md:19:genomic
content/02.tubaseq.md:19:genomic
content/02.tubaseq.md:19:lentiviral
content/02.tubaseq.md:19:lentiviral
content/02.tubaseq.md:19:lentiviruses
content/02.tubaseq.md:19:plasmids
content/02.tubaseq.md:19:recombinase
content/02.tubaseq.md:19:sgRNA
content/02.tubaseq.md:19:titer
content/02.tubaseq.md:19:titer
content/02.tubaseq.md:19:tumorigenesis
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:BRAF
content/02.tubaseq.md:21:catenin
content/02.tubaseq.md:21:catenin
content/02.tubaseq.md:21:histologic
content/02.tubaseq.md:21:tumorigenesis
content/02.tubaseq.md:21:tumorigenesis
content/02.tubaseq.md:21:Wnt
content/02.tubaseq.md:23:BRAF
content/02.tubaseq.md:23:BRAF
content/02.tubaseq.md:23:CRISPR
content/02.tubaseq.md:23:immunohistochemistry
content/02.tubaseq.md:23:immunohistochemistry
content/02.tubaseq.md:23:RNAs
content/03.p53.md:5:adenocarcinomas
content/03.p53.md:5:ARF
content/03.p53.md:5:BRAF
content/03.p53.md:5:BRAF
content/03.p53.md:5:BRAF
content/03.p53.md:5:dedifferentiation
content/03.p53.md:5:GEMMs
content/03.p53.md:5:GEMMs
content/03.p53.md:5:homologues
content/03.p53.md:5:hotspot
content/03.p53.md:5:hotspot
content/03.p53.md:5:MEK
content/03.p53.md:5:missense
content/03.p53.md:5:transcriptome
content/03.p53.md:5:vitro
content/03.p53.md:5:vivo
content/03.p53.md:9:BRAF
content/03.p53.md:9:BRAF
content/03.p53.md:9:BRAF
content/03.p53.md:9:EGFR
content/03.p53.md:9:EGFR
content/03.p53.md:9:EGFR
content/03.p53.md:9:GEMMs
content/03.p53.md:9:histologically
content/03.p53.md:9:KRAS
content/03.p53.md:9:KRAS
content/03.p53.md:9:KRAS
content/03.p53.md:9:LUAD
content/03.p53.md:9:LUAD
content/03.p53.md:9:LUAD
content/03.p53.md:9:MAPK
content/03.p53.md:9:MAPK
content/03.p53.md:9:mutationally
content/03.p53.md:9:oncoproteins
content/03.p53.md:9:pneumocyte
content/03.p53.md:9:Siegel
content/03.p53.md:9:transformative
content/03.p53.md:11:ARF
content/03.p53.md:11:chemoresistance
content/03.p53.md:11:genomic
content/03.p53.md:11:LUAD
content/03.p53.md:11:MDMX
content/03.p53.md:11:phenotypes
content/03.p53.md:11:proliferative
content/03.p53.md:11:TGF
content/03.p53.md:11:transcriptional
content/03.p53.md:11:transcriptional
content/03.p53.md:11:transcriptional
content/03.p53.md:13:BRAF
content/03.p53.md:13:BRAF
content/03.p53.md:13:dysregulation
content/03.p53.md:13:GEMMs
content/03.p53.md:13:homologues
content/03.p53.md:13:hotspots
content/03.p53.md:13:phenotypic
content/03.p53.md:13:tumorigenesis
content/03.p53.md:15:BRAF
content/03.p53.md:15:BRAF
content/03.p53.md:15:hotspot
content/03.p53.md:15:tumorigenesis
content/03.p53.md:15:tumorigenesis
content/03.p53.md:19:BRAF
content/03.p53.md:19:Differentially
content/03.p53.md:19:Tumorigenesis
content/03.p53.md:21:adenovirus
content/03.p53.md:21:BRAF
content/03.p53.md:21:BRAF
content/03.p53.md:21:Cre
content/03.p53.md:21:Cre
content/03.p53.md:21:Cre
content/03.p53.md:21:Dankort
content/03.p53.md:21:heterozygosity
content/03.p53.md:21:heterozygous
content/03.p53.md:21:LOH
content/03.p53.md:21:pfu
content/03.p53.md:21:pneumocytes
content/03.p53.md:21:recombinase
content/03.p53.md:21:Spc
content/03.p53.md:21:surfactant
content/03.p53.md:21:tumorigenic
content/03.p53.md:23:homozygous
content/03.p53.md:26:Dedifferentiation
content/03.p53.md:28:dedifferentiated
content/03.p53.md:28:dedifferentiation
content/03.p53.md:28:dedifferentiation
content/03.p53.md:28:dedifferentiation
content/03.p53.md:28:flfl
content/03.p53.md:28:IHC
content/03.p53.md:28:LUAD
content/03.p53.md:28:LUADs
content/03.p53.md:28:SPC
content/03.p53.md:28:SPC
content/03.p53.md:28:transcriptional
content/03.p53.md:30:ARF
content/03.p53.md:30:ARF
content/03.p53.md:30:ARF
content/03.p53.md:30:atypia
content/03.p53.md:30:BRAF
content/03.p53.md:30:heterozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:homozygous
content/03.p53.md:30:IHC
content/03.p53.md:30:immunofluorescence
content/03.p53.md:30:Immunohistochemistry
content/03.p53.md:30:immunostaining
content/03.p53.md:30:phospho
content/03.p53.md:30:transcriptional
content/03.p53.md:32:BRAF
content/03.p53.md:32:MEK
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAF
content/03.p53.md:34:BRAFi
content/03.p53.md:34:chemotherapies
content/03.p53.md:34:Cre
content/03.p53.md:34:dabrafenib
content/03.p53.md:34:dabrafenib
content/03.p53.md:34:dabrafenib
content/03.p53.md:34:Dabrafenib
content/03.p53.md:34:flfl
content/03.p53.md:34:homologue
content/03.p53.md:34:hotspot
content/03.p53.md:34:lentivirus
content/03.p53.md:34:MAPK
content/03.p53.md:34:MEK
content/03.p53.md:34:MEKi
content/03.p53.md:34:missense
content/03.p53.md:34:phosphorylated
content/03.p53.md:34:proliferative
content/03.p53.md:34:Spc
content/03.p53.md:34:trametinib
content/03.p53.md:34:trametinib
content/03.p53.md:34:Trametinib
content/03.p53.md:37:BRAF
content/03.p53.md:37:transcriptome
content/03.p53.md:39:dedifferentiation
content/03.p53.md:39:mesenchymal
content/03.p53.md:39:MYC
content/03.p53.md:39:phenotypes
content/03.p53.md:39:transcriptional
content/03.p53.md:39:transcriptional
content/03.p53.md:39:transcriptomic
content/03.p53.md:39:upregulated
content/03.p53.md:42:BRAF
content/03.p53.md:42:BRAF
content/03.p53.md:42:Cre
content/03.p53.md:42:Cre
content/03.p53.md:42:Cre
content/03.p53.md:42:Heterozygous
content/03.p53.md:42:homozygous
content/03.p53.md:42:Hotspot
content/03.p53.md:42:Recombinase
content/03.p53.md:42:tumorigenesis
content/03.p53.md:42:wildtype
content/03.p53.md:44:ARF
content/03.p53.md:44:ARF
content/03.p53.md:44:Colocalization
content/03.p53.md:44:dedifferentiation
content/03.p53.md:44:IHC
content/03.p53.md:44:Missense
content/03.p53.md:44:SPC
content/03.p53.md:47:BRAFi
content/03.p53.md:47:BRAFi
content/03.p53.md:47:BRAFi
content/03.p53.md:47:CytotoxRed
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:dabrafenib
content/03.p53.md:47:Ectopic
content/03.p53.md:47:GEMMs
content/03.p53.md:47:Immunoblotting
content/03.p53.md:47:MEKi
content/03.p53.md:47:MEKi
content/03.p53.md:47:phospho
content/03.p53.md:47:timecourse
content/03.p53.md:47:trametinib
content/03.p53.md:47:trametinib
content/03.p53.md:47:trametinib
content/03.p53.md:47:trametinib
content/03.p53.md:47:vitro
content/03.p53.md:47:vitro
content/03.p53.md:50:differentially
content/03.p53.md:50:GSEA
content/03.p53.md:50:transcriptome
content/03.p53.md:50:Upregulated
content/03.p53.md:52:differentially
content/03.p53.md:52:GSEA
content/03.p53.md:52:transcriptome
content/03.p53.md:52:Upregulated
content/03.p53.md:58:adenocarcinomas
content/03.p53.md:58:BRAF
content/03.p53.md:58:Cre
content/03.p53.md:58:Cre
content/03.p53.md:58:dedifferentiation
content/03.p53.md:58:hotspot
content/03.p53.md:58:leukemias
content/03.p53.md:58:missense
content/03.p53.md:58:missense
content/03.p53.md:58:wildtype
content/03.p53.md:58:wildtype
content/03.p53.md:58:wildtype
content/03.p53.md:60:BRAF
content/03.p53.md:60:BRAF
content/03.p53.md:60:dabrafenib
content/03.p53.md:60:heterozygosity
content/03.p53.md:60:missense
content/03.p53.md:60:trametinib
content/03.p53.md:60:tumorigenesis
content/03.p53.md:60:wildtype
content/03.p53.md:60:wildtype
content/03.p53.md:64:adenocarcinomas
content/03.p53.md:64:ARF
content/03.p53.md:64:ARF
content/03.p53.md:64:ARF
content/03.p53.md:64:ARF
content/03.p53.md:64:ARF
content/03.p53.md:64:ARF
content/03.p53.md:64:BRAF
content/03.p53.md:64:BRAF
content/03.p53.md:64:GOF
content/03.p53.md:64:Hyperactivation
content/03.p53.md:64:MAPK
content/03.p53.md:64:MAPK
content/03.p53.md:64:oncogenic
content/03.p53.md:64:PDAC
content/03.p53.md:64:phospho
content/03.p53.md:66:GOF
content/03.p53.md:66:oligomerization
content/03.p53.md:66:transactivation
content/03.p53.md:66:transcriptional
content/03.p53.md:66:transcriptomes
content/03.p53.md:68:BRAF
content/03.p53.md:68:BRAF
content/03.p53.md:68:BRAF
content/03.p53.md:68:chemotherapies
content/03.p53.md:68:GOF
content/03.p53.md:68:Imatinib
content/03.p53.md:68:immunoblotting
content/03.p53.md:68:ligands
content/03.p53.md:68:LSL
content/03.p53.md:68:MEK
content/03.p53.md:68:PDGF
content/03.p53.md:68:PDGFR
content/03.p53.md:68:PDGFR
content/03.p53.md:68:phenotypes
content/03.p53.md:68:transcriptional
content/03.p53.md:70:dabrafenib
content/03.p53.md:70:dedifferentiation
content/03.p53.md:70:pre
content/03.p53.md:70:proliferative
content/03.p53.md:70:trametinib
content/03.p53.md:70:transcriptomes
content/03.p53.md:70:tumorigenic
